Pemafibrate

Pemafibrate is a drug used in the treatment of hyperlipidemia, specifically hypertriglyceridemia. It is a selective peroxisome proliferator-activated receptor alpha (PPARα) modulator (SPPARMα) that was developed by Kowa Company and is marketed in Japan under the brand name Parmodia.

Mechanism of Action

Pemafibrate works by selectively activating PPARα, a nuclear receptor that plays a crucial role in the metabolism of lipids. This activation leads to an increase in the breakdown and removal of triglycerides from the body, thereby reducing their levels in the blood.

Medical Uses

Pemafibrate is used for the treatment of hypertriglyceridemia, a condition characterized by high levels of triglycerides in the blood. It is particularly effective in patients who have not responded adequately to other treatments, such as dietary changes and exercise.

Side Effects

Common side effects of pemafibrate include nausea, diarrhea, and abdominal pain. In rare cases, it can cause more serious side effects such as liver damage and pancreatitis.

History

Pemafibrate was developed by Kowa Company and was first approved for use in Japan in 2017. It is currently being studied for potential use in other countries.

See Also

• Hyperlipidemia
• Hypertriglyceridemia
• Peroxisome proliferator-activated receptor alpha
• Kowa Company

Pemafibrate Resources
Latest articles Most recent articles Ongoing trials	Wikipedia